fbpx

The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD

  • Posted by Jenna Widdison
  • On November 11, 2019
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPD GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr Valve, are a proven, viable, minimally-invasive treatment option for severe emphysema, a form […]
Read More

Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer

  • Posted by Jenna Widdison
  • On May 9, 2019
Financing to Expand the U.S. Launch and Global Commercialization of the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema/COPD REDWOOD CITY, California, May 9, 2019 – Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick […]
Read More

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • Posted by Jenna Widdison
  • On August 1, 2018
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment New labeling clears the way for the treatment of many more patients. January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an...
Read More

Pulmonx Reports New Publication Confirms Efficacy of Emphysema Treatment

  • Posted by Jenna Widdison
  • On August 1, 2018
Zephyr® Endobronchial Valve (EBV) therapy guided by Chartis®Assessment is effective in a broad range of patients. May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the...
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • Posted by Jenna Widdison
  • On August 1, 2018
IDE for Study of Zephyr® Endobronchial Valve Approved August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to...
Read More

FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema

  • Posted by Chris Kellett
  • On June 29, 2018
REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for
Read More

Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial

  • Posted by Jenna Widdison
  • On May 22, 2018
SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)....
Read More

UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

  • Posted by Jenna Widdison
  • On November 20, 2017
REDWOOD CITY, Calif. – December 20, 2017 – Pulmonx® Corp. today announced that the UK's National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now...
Read More

New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility and Quality of Life for Emphysema Patients

  • Posted by Jenna Widdison
  • On September 8, 2017
REDWOOD CITY, Calif. – September 8, 2017 – Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in the American Journal of Respiratory and Critical Care...
Read More

New Data from Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit to Both Heterogeneous and Homogenous Emphysema Patients without Collateral Ventilation

  • Posted by Jenna Widdison
  • On May 23, 2017
Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without...
Read More

Pulmonx Completes Enrollment in U.S. Pivotal Trial of Zephyr®Endobronchial Valve

  • Posted by Jenna Widdison
  • On October 5, 2016
Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema,...
Read More